Introduction. Intravenous thrombolysis with recombinant plasminogen activator is proven to be beneficial for patients with ischaemic stroke. Intracerebral hemorrhage represents the most serious complication of the treatment mentioned. Aim of this study. The aim of this retrospective study is a detailed analysis of intracranial hemorrhagic complications treated with recombinanttissue plasminogen activator. Patients and Methods. All intracerebral hemorrhage patients were classified according to the European Cooperative Acute Stroke Studyprotocol recommendations. A total of 188 patients were treated with thrombolytic therapy. Overall incidence of hemorrhagic complications was 22.3%, while the frequency of intracranial hemorrhagic events was 17%. The incidence of symptomatic intracranial hemorrhage was recorded in 6.9%, and the percentage of deaths after thrombolysis was in 5.3% of patients. Conclusion. The most common cause of deterioration in patients treated with recombinantt issue plasminogen activator is the occurrence of parenchymal hematoma type 2.Other forms of intracerebral hemorrhage after thrombolysis did not lead to clinical deteriorations. If existing recommendations are followed, thrombolytic therapy is safe.